Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.61 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 9/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091128 | 0.83 | HPGD (0.59) | LMNAALDH1A1MAPTMEN1HPGD | |
| SCHEMBL1025382 | 0.82 | APEX1 (0.69) | APEX1CASP6LMNATSHRALDH1A1 | |
| SCHEMBL1025384 | 0.80 | APEX1 (0.66) | APEX1CASP6LMNATSHRALDH1A1 | |
| SCHEMBL856086 | 0.80 | APEX1 (0.66) | APEX1CASP6LMNATSHRALDH1A1 | |
| SCHEMBL3866808 | 0.80 | APEX1 (0.66) | APEX1CASP6LMNATSHRALDH1A1 | |
| SCHEMBL466008 | 0.78 | TXNRD1 (0.66) | LMNATSHRALDH1A1MAPTMEN1 | |
| SCHEMBL29350780 | 0.78 | TXNRD1 (0.66) | LMNATSHRALDH1A1MAPTMEN1 | |
| SCHEMBL28121409 | 0.76 | TXNRD1 (0.64) | LMNATSHRALDH1A1MAPTMEN1 | |
| SCHEMBL288907 | 0.76 | CASP6 (0.64) | APEX1CASP6LMNATSHRHCAR3 | |
| SCHEMBL3407384 | 0.76 | TDP1 (0.58) | TSHRALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | disclosed |
| CN-1742007-A | Indole-derivative modulators of steroid hormone nuclear receptors | LILLY CO ELI (US) | 2006-03-01 | — | — | CN | disclosed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | NR3C2, NR5A1, MC2R | APEX1 4546/4885CASP6 4795/4885LMNA 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.